Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

References

• Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB, Orlock DA. The expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathy. Arch Ophthalmol. 1997;115(4):478–485. doi:10.1001/archopht.1997.01100150480005
   PubMedGoogle Scholar
• Wong CW, Yanagi Y, Lee WK, et al. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016;53:107–139. doi:10.1016/j.preteyeres.2016.04.002
   PubMed Web of Science ®Google Scholar
• Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144(1):15–22. doi:10.1016/j.ajo.2007.03.047
   PubMed Web of Science ®Google Scholar
• Lim TH, Lai TYY, Takahashi K, et al. Comparison of ranibizumab with or without verteporfin photodynamic therapy for polypoidal choroidal vasculopathy: the EVEREST II randomized clinical trial. JAMA Ophthalmol. 2020;138(9):935–942. doi:10.1001/jamaophthalmol.2020.2443
   PubMed Web of Science ®Google Scholar
• Morimoto M, Matsumoto H, Mimura K, Akiyama H. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):1891–1897. doi:10.1007/s00417-017-3718-6
   PubMed Web of Science ®Google Scholar
• Japanese Study Group of Polypoidal Choroidal Vasculopathy. ポリープ状脈絡膜血管症の診断基準 [Criteria for diagnosis of polypoidal choroidal vasculopathy]. Nippon Ganka Gakkai Zasshi. 2005;109(7):417–427. Japanese.
   PubMedGoogle Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report. Arch Ophthalmol. 1999;117(10):1329–1345. doi:10.1001/archopht.117.10.1329
   PubMed Web of Science ®Google Scholar
• Holz FG, Sadda SR, Staurenghi G, et al. Imaging protocols in clinical studies in advanced age-related macular degeneration: recommendations from the classification of atrophy consensus meetings. Ophthalmology. 2017;124(4):464–478. doi:10.1016/j.ophtha.2016.12.002
   PubMed Web of Science ®Google Scholar
• Kuroda Y, Yamashiro K, Ooto S, et al. Macular atrophy and macular morphology in aflibercept-treated neovascular age-related macular degeneration. Retina. 2018;38(9):1743–1750. doi:10.1097/IAE.0000000000001765
   PubMed Web of Science ®Google Scholar
• Rasband WS. ImageJ. U. S. National Institutes of Health, Bethesda, MD; 1997–2012.
   Google Scholar
• Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671–675. doi:10.1038/nmeth.2089
   PubMed Web of Science ®Google Scholar
• Matsumoto H, Morimoto M, Mimura K, Ito A, Akiyama H. Treat-and-extend regimen with aflibercept for neovascular age-related macular degeneration: efficacy and macular atrophy development. Ophthalmol Retina. 2018;2(5):462–468. doi:10.1016/j.oret.2017.09.002
   PubMedGoogle Scholar
• Hosokawa M, Morizane Y, Hirano M, et al. One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy. Jpn J Ophthalmol. 2018;61(2):150–158. doi:10.1007/s10384-016-0492-7
   Web of Science ®Google Scholar
• Yamamoto A, Okada AA, Nakayama M, Yoshida Y, Kobayashi H. One-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degeneration. Ophthalmologica. 2017;237(3):139–144. doi:10.1159/000458538
   PubMed Web of Science ®Google Scholar
• Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151(4):594–603.e1. doi:10.1016/j.ajo.2010.10.030
   PubMed Web of Science ®Google Scholar
• Cho HJ, Kim K, Lim SH, Kang DH, Kim JW. Retinal pigment epithelial atrophy after anti-vascular endothelial growth factor therapy for polypoidal choroidal vasculopathy. Br J Ophthalmol. 2020;104(10):1443–1447. doi:10.1136/bjophthalmol-2019-315496
   PubMed Web of Science ®Google Scholar
• Choi EY, Park SE, Lee SC, et al. Long-term incidence and growth of chorioretinal atrophy in patients with polypoidal choroidal vasculopathy. Ophthalmologica. 2020;243(2):136–144. doi:10.1159/000501724
   PubMed Web of Science ®Google Scholar
• Koizumi H, Yamamoto A, Ogasawara M, et al. Macular atrophy after aflibercept therapy for neovascular age-related macular degeneration: outcomes of Japanese multicenter study. Jpn J Ophthalmol. 2020;64(4):338–345. doi:10.1007/s10384-020-00745-0
   PubMed Web of Science ®Google Scholar
• Hikichi T, Higuchi M, Matsushita T, et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol. 2012;154(1):117–124.e1. doi:10.1016/j.ajo.2011.12.019
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, et al. Everest study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32(8):1453–1464. doi:10.1097/IAE.0b013e31824f91e8
   PubMed Web of Science ®Google Scholar
• Mori R, Yuzawa M, Akaza E, et al. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity. Jpn J Ophthalmol. 2013;57(4):365–371. doi:10.1007/s10384-013-0245-9
   PubMed Web of Science ®Google Scholar
• Sato T, Kishi S, Matsumoto H, Mukai R. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(1):95–105.e1. doi:10.1016/j.ajo.2013.02.006
   PubMed Web of Science ®Google Scholar
• Gomi F, Oshima Y, Mori R, et al. Initial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathy: the Fujisan Study. Retina. 2015;35(8):1569–1576. doi:10.1097/IAE.0000000000000526
   PubMed Web of Science ®Google Scholar
• Koizumi H, Kano M, Yamamoto A, et al. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol. 2015;99(9):1284–1288. doi:10.1136/bjophthalmol-2014-306432
   PubMed Web of Science ®Google Scholar
• Yamamoto A, Okada AA, Kano M, et al. One-year results of intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122(9):1866–1872. doi:10.1016/j.ophtha.2015.05.024
   PubMed Web of Science ®Google Scholar
• Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(2):311–316. doi:10.1007/s00417-016-3467-y
   PubMed Web of Science ®Google Scholar
• Lee WK, Iida T, Ogura Y, et al. Efficacy and safety of intravitreal aflibercept for polypoidal choroidal vasculopathy in the PLANET study: a randomized clinical trial. JAMA Ophthalmol. 2018;136(7):786–793. doi:10.1001/jamaophthalmol.2018.1804
   PubMed Web of Science ®Google Scholar